Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CTD" target="_blank" >RIV/61988987:17110/21:A2202CTD - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/21:E0109006 RIV/00216208:11110/21:10438210 RIV/65269705:_____/21:00074360 RIV/00064165:_____/21:10438210

Výsledek na webu

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000646325700001?SID=D1v41LNKnqSuWlaZyU6" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000646325700001?SID=D1v41LNKnqSuWlaZyU6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.26172" target="_blank" >10.1002/ajh.26172</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Popis výsledku v původním jazyce

Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and >= 65 years, nonfrail and frail). Patients >= 65 years with XVd had higher ORR (OR 1.77, p = .024), >= VGPR (OR, 1.68, p = .027), PFS (HR 0.55, p = .002), and improved OS (HR 0.63, p = .030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p = .08) and OS (HR 0.62, p = .062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, >= VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade >= 2 peripheral neuropathy in >= 65 year-old (22% vs. 37%; p = .0060) and frail patients (15% vs. 44%; p = .0002). Grade >= 3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and >= 65 and in nonfrail and frail patients with previously treated MM.

Název v anglickém jazyce

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Popis výsledku anglicky

Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and >= 65 years, nonfrail and frail). Patients >= 65 years with XVd had higher ORR (OR 1.77, p = .024), >= VGPR (OR, 1.68, p = .027), PFS (HR 0.55, p = .002), and improved OS (HR 0.63, p = .030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p = .08) and OS (HR 0.62, p = .062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, >= VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade >= 2 peripheral neuropathy in >= 65 year-old (22% vs. 37%; p = .0060) and frail patients (15% vs. 44%; p = .0002). Grade >= 3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and >= 65 and in nonfrail and frail patients with previously treated MM.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Hematology

ISSN

0361-8609

e-ISSN

—

Svazek periodika

96

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

708-718

Kód UT WoS článku

000646325700001

EID výsledku v databázi Scopus

—